Navigation Links
Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop

ontraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been repor
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:9/17/2014)... 17, 2014  NuView Life Sciences, Inc. (NuView) ... collaboration agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) ... diagnostic biomarker to detect cancers of the breast ... future diagnostic-imaging applications. NuView retains all rights for ... in-vitro urine screen applications. Under the ...
(Date:9/17/2014)... CITY, Kan. , Sept. 17, 2014  Aratana ... pet therapeutics company focused on licensing, developing and ... announced the pricing of its public offering of 4,500,000 shares ... the public of $9.25 per share. Aratana has ... up to an additional 675,000 shares of its ...
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
Breaking Medicine Technology:NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
... Oct. 19 The board of directors of Eli Lilly and ... fourth quarter of 2009 of $0.49 a share on outstanding common ... the first three quarters of 2009 and brings the total annual ... http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) , The dividend is payable December ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
(Date:9/17/2014)... The Oliver Law Group P.C. is urging ... Non-Sterile Other-Sonic Ultrasound Transmission Gel to contact the ... legal recourse. Other-Sonic ultrasound gel was recalled by the ... after the product was linked to a 2011 outbreak ... Royal Oak, Michigan . While victims of this outbreak ...
(Date:9/17/2014)... Tidewater Physical Therapy and ... for football players and their parents at its Newport ... open at 6:30 p.m. for athletes and parents to ... and physical therapists. The workshop will start at 7 ... News Tidewater Performance Center, which features sports performance and ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
(Date:9/17/2014)... September 18, 2014 Many countries choose ... instead of immunizations. The total number of poultry exceeds ... to control, will result in huge losses. Therefore, it ... influenza vaccines. , Avian influenza vaccines have been used ... farms in China began to use H5N1 avian influenza ...
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
Breaking Medicine News(10 mins):Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3
... not as interested in information on lifestyle changes , FRIDAY, ... the recent deluge of scientific discoveries of links between specific ... healthy people with something they don,t need: an excuse for ... people are going to use genetics as a way to ...
... Washington, are more likely to be obese if they ... a team of researchers at Seattle Children,s Research Institute, ... Institute. Social Science & Medicine e-published the ... The researchers found obesity most common in children ...
... Center for Neural Science, has been named the recipient ... work on how the brain reconstructs images, the Lisbon-based ... William T. Newsome, a Stanford University neuroscientist. ... prize, the largest monetary prize in the field of ...
... at the University of Leicester is examining a sequence of ... individual. This follows evidence that these structures shrink in ... to several diseases including those commonly associated with ageing and, ... study is trying to understand how this process is controlled. ...
... a youth club, they gain a stronger sense of who ... has revealed. The study suggests that even small improvements ... out of trouble. "The more kids participate in these ... an associate professor of social work at Ohio State. "And ...
... Genomics Consortium (SGC) and Pfizer today announced that Pfizer ... molecule inhibitors "chemical probes" for proteins involved ... now members of this collaboration, launched in late 2008 ... quality research reagents, free from restriction on use. ...
Cached Medicine News:Health News:Least Healthy More Apt to Think Genes Explain Disease Risk 2Health News:Least Healthy More Apt to Think Genes Explain Disease Risk 3Health News:Least Healthy More Apt to Think Genes Explain Disease Risk 4Health News:Childhood obesity linked to neighborhood social and economic status 2Health News:Childhood obesity linked to neighborhood social and economic status 3Health News:NYU's Movshon receives Champalimaud Vision Award for work on how brain reconstructs images 2Health News:Size matters -- when it comes to DNA 2Health News:Youth clubs strengthen kids' self image to keep them out of trouble 2Health News:Youth clubs strengthen kids' self image to keep them out of trouble 3Health News:Pfizer joins open-access medicinal chemistry public-private collaboration 2
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: